# Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies

> **NCT06948097** · PHASE1 · NOT_YET_RECRUITING · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 30 (estimated)

## Conditions studied

- Lung Transplantation

## Interventions

- **DRUG:** fostamatinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06948097
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-21
- **Primary completion:** 2028-07-14
- **Final completion:** 2028-07-14
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06948097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06948097, "Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06948097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*